其中：净买入阿里巴巴-W 34.43亿(昨日净买入亿港元49.21亿)、盈富基金25.24亿、腾讯控股4.92亿、长 飞光纤光缆3.57亿、地平线机器人-W 2.89亿、康方生物1.92亿；净卖出中芯国际10.37亿、华虹半导体 10.15亿、小米集团-W 4.1亿、中兴通讯1.9亿。 据统计，南下资金已连续8日净买入阿里巴巴，共计143.3952亿港元；连续3日净买入腾讯，共计33.1065 亿港元；连续8日净卖出小米，共计54.0657亿港元。 北水关注个股 阿里巴巴-W：瑞穗证券将阿里巴巴目标价从149美元上调至159美元。 9月2日，南下资金净买入港股92.81亿港元。 长飞光纤光缆：上半年营业收入63.85亿人民币，同比增加19.4%；纯利2.96亿元，下滑21.7%，每股收 益39分。公司称，目前，空芯光纤相关业务尚未对公司财务数据产生明显影响。 康方生物：里昂发布研报称，将康方生物目标价从112.6港元升至177港元，维持跑赢大市评级。 中芯国际：上半年中芯国际实现营收323.48亿元人民币，同比增长23.1%；实现归母净利润23亿元，同 比增长39.8%；息税折旧及摊销前利润174.18亿元， ...

Core Viewpoint - The recent adjustments to the Hang Seng Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index aim to refine the indices by removing companies primarily involved in the CXO (Contract Research Organization, Contract Manufacturing Organization, and Contract Development and Manufacturing Organization) sector, thereby better reflecting the trends in the innovative drug industry [1][2][3]. Index Adjustments - The Hang Seng Innovation Drug Index has reduced its constituent stocks from 36 to 29 by removing 7 companies, while the Hang Seng Hong Kong Stock Connect Innovation Drug Index has decreased from 34 to 29 by excluding 5 companies [1][3]. - The removed CXO companies previously accounted for approximately 20% of the weight in the Hang Seng Hong Kong Stock Connect Innovation Drug Index, which is expected to enhance the index's ability to reflect the development trends of the innovative drug industry [1][2]. Performance Metrics - Historical data shows that the revised index has improved its performance, with the annualized return increasing from 3.2% to 8.2% for 2023, and from -11.5% to -4.5% for 2024 [4]. - The Hang Seng Innovation Drug Index is projected to achieve its first annual increase since 2020, with a year-to-date increase of 116% as of August 22, 2025, outperforming the broader market and the healthcare sector [4]. CXO Sector Insights - The removal of CXO companies, particularly those from the WuXi AppTec group, may lead to short-term capital outflows but could be offset by long-term industry recovery trends and strategic adjustments by the companies [5][6]. - Despite being removed from the indices, several CXO companies reported strong performance in the first half of the year, with WuXi Biologics achieving a revenue of 9.95 billion yuan, a year-on-year increase of 16.1% [5]. Future Outlook - Analysts suggest that the CXO sector is poised for recovery, driven by the increasing demand for clinical trial services and the strategic direction of domestic innovative drug companies [6]. - The CXO industry is expected to benefit from the competitive advantages of being a major production country, alongside a favorable regulatory environment and the rising complexity of new drug development [6].

Core Insights - The competitiveness of the biopharmaceutical industry ultimately reflects the cluster effect [1][11] - The biopharmaceutical industry is a core track of global technological revolution and industrial transformation, serving as a key indicator of regional economic high-quality development [2] Industry Development - The Yangtze River Delta region, centered around Shanghai Zhangjiang and Suzhou BioBAY, has established a first-mover advantage in the biopharmaceutical field due to early policy layouts, dense research resources, and a complete industrial chain [2] - Guangzhou Huangpu District has not lagged despite being a latecomer; it has optimized its policy system, built talent aggregation platforms, and focused on breakthroughs in niche markets, gradually compensating for industrial chain shortcomings [2][12] Key Companies and Innovations - Yunzhou Biotech, founded by Dr. Lan Tian in Huangpu District in 2014, focuses on gene delivery, a critical link between basic research and clinical application [3] - The company developed the world's first intelligent design and ordering platform for gene carriers, integrating over 120 carrier systems and more than 2 million carrier components, significantly lowering the barriers for researchers [4][5] - Yunzhou Biotech has become the world's largest custom gene carrier supplier, serving over 7,000 institutions in more than 130 countries, with a cumulative delivery of over 1 million carriers by September 2024 [5][6] Market Position and Achievements - In 2023, Yunzhou Biotech achieved a valuation of 7 billion, becoming a unicorn and the first biopharmaceutical company in Guangzhou to reach this status [6] - The company has established a full-service capability in the gene drug development chain, including CRO and CDMO services, with its products approved for clinical trials in the U.S. [6][7] Competitive Landscape - Innovation in drug development is a core competitive advantage in the biopharmaceutical industry, with companies like Kangfang Biopharma emerging as leaders in the field [8] - Kangfang Biopharma has developed over 50 innovative drug candidates, with 24 products undergoing clinical trials, and has successfully commercialized 7 first-class new drugs [10] Ecosystem and Collaboration - Huangpu District's "bending overtaking" is not merely the success of a single enterprise but a result of creating a quality industrial ecosystem that fosters collaboration between leading external companies and local enterprises [12] - The presence of major companies like Hengrui Medicine and Nuocheng Jianhua in Huangpu has attracted a network of supporting enterprises, enhancing the regional industrial chain [13][14]

Investment Rating - The report maintains a strong buy rating for the pharmaceutical sector, indicating a bullish outlook for the industry [3]. Core Insights - The pharmaceutical sector is expected to experience a broad rally, driven by innovative drugs leading the charge. The sector index showed a notable upward trend in the first half of 2025, particularly in April, with a valuation premium of 275.19%, significantly above historical averages [4][18]. - Public funds are increasingly favoring pharmaceutical stocks, particularly in innovative drugs and medical devices, supported by stable growth in basic medical insurance funds [4][22]. Section Summaries 1. Market Performance - The pharmaceutical sector has shown a strong upward trend since Q3 2024, outperforming the broader market indices. The sector index rose by 24.51% from the beginning of 2025 to August 29, 2025, surpassing the Shanghai and Shenzhen 300 index by 11.07 percentage points [11][12]. - Medical services and chemical raw materials have performed particularly well, with medical services up by 80.24% and chemical raw materials up by 53.67% as of August 28, 2025 [17]. 2. Industry Overview - The pharmaceutical manufacturing industry has shown resilience, with stable revenue growth and a healthy operating environment for basic medical insurance funds. The overall revenue of the pharmaceutical manufacturing industry has experienced fluctuations but is on a recovery path [31][35]. - The innovative drug business development (BD) has seen explosive growth, with China becoming a hotspot for multinational corporations (MNCs) seeking partnerships. The total transaction amount for BD in 2024 reached a record high of $640.8 billion, with significant contributions from overseas transactions [36][38]. 3. Subsector Analysis - Innovative drugs are leading the growth, with 21 A-share innovative drug companies reporting a revenue of 28.69 billion yuan in the first half of 2025, a year-on-year increase of 42%. The net profit loss has narrowed significantly, indicating a positive trend in profitability [56]. - The medical device sector is also expected to see a turning point in the second half of 2025, with a 62.75% year-on-year growth in the overall bidding market for medical devices in the first half of 2025, exceeding 80 billion yuan [52].

Core Insights - On September 2, 2025, Alibaba-W (09988), Xiaomi Group-W (01810), and SMIC (00981) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 86.47 billion, 60.46 billion, and 59.59 billion respectively [1] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, SMIC (00981), Alibaba-W (09988), and Xiaomi Group-W (01810) also ranked as the top three, with trading amounts of 48.12 billion, 45.52 billion, and 34.29 billion respectively [1] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 86.47 billion, net buying of +20.88 billion [2] - Xiaomi Group-W (01810): Trading amount of 60.46 billion, net selling of -5.92 billion [2] - SMIC (00981): Trading amount of 59.59 billion, net buying of +4.18 billion [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)** - SMIC (00981): Trading amount of 48.12 billion, net selling of -14.55 billion [2] - Alibaba-W (09988): Trading amount of 45.52 billion, net buying of +13.55 billion [2] - Xiaomi Group-W (01810): Trading amount of 34.29 billion, net buying of +1.81 billion [2]

每经AI快讯，9月2日，恒生指数下跌0.47%。南向资金今日净买入92.81亿港元。 | 代码 | 简称 | 收盘价 (港元) | 涨跌幅 (%) | 净买入金额 (亿港元) | | | --- | --- | --- | --- | --- | --- | | 9988.HK | 阿里巴巴-W | 134.7 | -1.75 | 34.43 | . | | 0700.HK | 腾讯控股 | 600.5 | -0.74 | 4.93 | . | | 6869 HK | 长飞光纤光缆 | 44.98 | -12.15 | 3.57 | . | | 9660.HK | 地平线机器人-W | 9.56 | 1.27 | 2.90 | | | 9926.HK | 康方生物 | 155.8 | -1.39 | 1.92 | | | 9880.HK | 优必选 | 105.5 | 5.18 | -0.45 | | | 3690.HK | 美团-W | 101.1 | -1.84 | -0.72 | . | | 0763.HK | 中兴通讯 | 33.4 | -7.79 | -1.90 | . | | 1810.HK | ...

Group 1 - Southbound funds net bought Hong Kong stocks worth 9.281 billion HKD today [1] - Net purchases included Alibaba-W at 3.443 billion HKD, the Tracker Fund at 2.524 billion HKD, Tencent Holdings at 492 million HKD, and others [1] - Southbound funds have net bought Alibaba for 8 consecutive days, totaling 14.33952 billion HKD [1] Group 2 - Net sales included SMIC at 1.037 billion HKD, Hua Hong Semiconductor at 1.015 billion HKD, and Xiaomi Group-W at 410 million HKD [1] - Southbound funds have net sold Xiaomi for 8 consecutive days, totaling 5.40657 billion HKD [1]

Core Insights - Northbound capital recorded a net purchase of HKD 92.81 billion in the Hong Kong stock market on September 2, with a total annual net purchase exceeding HKD 1 trillion, marking the highest since the launch of the Stock Connect mechanism [1][2] Group 1: Stock Performance - Alibaba-W (09988) was the most bought stock, with a net purchase of HKD 53.68 billion, while it had a total transaction volume of HKD 86.47 billion [2][4] - Xiaomi Group-W (01810) faced a net sell of HKD 4.1 billion, with total transactions amounting to HKD 60.46 billion [2][7] - Semiconductor stocks, SMIC (00981) and Hua Hong Semiconductor (01347), experienced significant net sells of HKD 10.36 billion and HKD 10.14 billion respectively [6] Group 2: Analyst Insights - Morgan Stanley reported that Alibaba's delivery and instant retail business has reached a scalable level, expecting a reduction in losses for Ele.me in the coming quarters [4] - CICC highlighted that despite short-term liquidity issues affecting Hong Kong stocks, long-term structural advantages remain significant [5] - UBS expressed optimism about Horizon Robotics (09660) following a successful investor meeting, anticipating growth driven by design orders from multiple automotive manufacturers [5] Group 3: Market Trends - The net buying trend from Northbound capital indicates a strong interest in major tech stocks, particularly Alibaba and Tencent, which received net purchases of HKD 34.43 billion and HKD 4.92 billion respectively [4][5] - The semiconductor sector is facing pressure, with analysts suggesting that the market may have been overly optimistic about companies like ZTE Corporation (00763) due to disappointing earnings [6]

Group 1 - The core viewpoint of the news highlights the performance of Qianhai Kaiyuan Medical Health A and C funds, which experienced declines of 1.82% and 1.83% respectively in August, while the Shanghai Composite Index rose by 7.97% during the same period [1][2] - Since their inception on January 19, 2018, the cumulative returns for Qianhai Kaiyuan Medical Health A and C funds are 37.51% and 36.47% respectively, with a decline of 10.71% and 10.98% over the past three years [1] - As of June 30, 2025, the total scale of Qianhai Kaiyuan Medical Health A and C funds is 1.011 billion yuan [1] Group 2 - The top ten holdings of Qianhai Kaiyuan Medical Health A/C funds include companies such as Sanofi, Dizh Medical, Innovent Biologics, and others [1] - The fund is currently managed by Fan Jie, who has been with Qianhai Kaiyuan Fund Management Company since 2014 and has held various positions including research analyst and investment manager [1]

Investment Rating - The report maintains a "Buy" rating for the company [2][16][28] Core Insights - The company reported a 37.8% year-on-year revenue growth in the first half of 2025, reaching RMB 1.41 billion, with net losses of RMB 570 million, aligning with expectations [5][12] - Key product sales, particularly cadonilimab and ivonescimab, have ramped up significantly following their inclusion in the National Reimbursement Drug List (NRDL) [5][12] - The company has a strong cash reserve of approximately RMB 7.14 billion as of June 2025 [5][12] Financial Data and Profit Forecast - Revenue projections for 2025E are set at RMB 3.15 billion, with a year-on-year growth rate of 48.38% [10] - The forecast for net profit attributable to shareholders for 2025E is a loss of RMB 870 million, with subsequent years showing a recovery to RMB 1.57 billion by 2027E [10] - Earnings per share (EPS) estimates have been adjusted downwards for 2025E to -RMB 0.97, with a gradual recovery expected in the following years [10][16] Clinical Development and Pipeline Expansion - The AK112 clinical trial has achieved significant overall survival (OS) benefits, with multiple indications under development, including NSCLC [6][13] - Cadonilimab (AK104) is undergoing extensive clinical trials for various indications, with three already approved by the NMPA [7][14] - The company is expanding its non-oncology pipeline, with new products and ongoing clinical trials for several indications [8][15] Target Price Adjustment - The target price has been raised from HK$ 87 to HK$ 189, indicating a potential upside of 21% [16]